Imagene is pioneering the use of AI-powered foundation models trained on over 1.5 million biopsy images across 40 tissue types to enhance precision oncology. Their Oncology Intelligence (OI) platform integrates genomic, proteomic, and spatial biomarker data to predict patient responses, stratify for clinical trials, and identify novel drug targets. The Miami-based startup has raised significant funding backed by investors such as Oracle founder Larry Ellison, focusing on creating tools that assist physicians and drug developers in making informed treatment decisions and optimizing clinical trial design.